Modifying the course of chronic obstructive pulmonary disease: Looking beyond the FEV1

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 6, 2012, Pages 637-648

  Zuwallack, Richard L ^a   Nici, Linda ^b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

COPD; Dyspnea; Exacerbations; Maintenance pharmacotherapy; Mortality; Progression

Indexed keywords

ANXIETY; ATROPHY; BODY MASS; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; COR PULMONALE; CORONARY ARTERY DISEASE; CORTICOSTEROID INDUCED MYOPATHY; DEPRESSION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HUMAN; HYPERINFLATION; LUNG CANCER; LUNG FUNCTION TEST; METABOLIC SYNDROME X; MORTALITY; MUSCLE ATROPHY; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SIX MINUTE WALKING DISTANCE TEST; SLEEP DISORDERED BREATHING; SMOKING CESSATION;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DYSPNEA; EXERCISE TEST; FORCED EXPIRATORY VOLUME; HUMANS; PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY SYSTEM AGENTS; RESPIRATORY THERAPY; SEVERITY OF ILLNESS INDEX; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84871482916     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.710668     Document Type: Review

References (114)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun; 23(6):932-946.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. [Internet]. Bethesda, MD; 2011. Available from: http:// www.goldcopd.org/guidelines-global-strategy-for- diagnosismanagement. html.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176(6):532-555.
4. Fletcher C, Peto R. The natural history of chronic airfl ow obstruction. Br Med J 1977 Jun 25; 1(6077):1645-1648.
5. Marsh S, Aldington S, Shirtcliff e P, Weatherall M, Beasley R. Smoking and COPD: What really are the risks? Eur Respir J 2006 Oct; 28(4):883-884.
6. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006 Apr 15; 367(9518):1216-1219.
7. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S, Sandstrom T, Larsson K. Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003 Feb; 97(2):115-122.
8. World Health Organization. Chronic obstructive pulmonary disease. Fact sheet No. 315. [Internet]. 2008. Available from: http://www.who.int/mediacentre/ factsheets/fs315/en
9. American Lung Association. Chronic obstructive pulmonary disease (COPD). [Internet]. Washington, DC; 2008. Available from: http://www.lungusa.org/assets/ documents/ publications/lung-disease-data/ldd08-chapters/LDD-08- COPD.pdf
10. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007 Sep 1; 370(9589):765-773.
11. Minino AM, Xu J, Kochanek KD. Deaths: preliminary data for 2008. Natl Vital Stat Rep 2010; 59(2):1-52.
12. US National Heart Lung and Blood Institute. Morbidity and Mortality: the 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institutes of Health; 2009.
13. The ASPECT Consortium. Tobacco or Health in the European Union: Past, Present, and Future. In: European Bureau for Action on Smoking Prevention Brussels, Belgium: European Commission; 2004.
14. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005 Jun; 99(6):670-682.
15. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of survival in COPD: more than just the FEV1. Respir Med 2008 Jun; 102 Suppl 1:S27-35.
16. Jones PW. Health status and the spiral of decline. COPD 2009 Feb; 6(1):59-63.
17. Wolkove N, Dajczman E, Colacone A, Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989 Dec; 96(6):1247-1251.
18. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002 May; 121(5):1434-1440.
19. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 Mar 15; 171(6):591-597.
20. Connors AF, Jr., Dawson NV, Thomas C, Harrell FE, Jr., Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996 Oct; 154(4 Pt 1):959-967.
21. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 Mar 4; 350(10):1005-1012.
22. Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, Maltais F. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 Sep 15; 166(6):809-813.
23. O'Donnell DE, Laveniziana P. Physiology and consequences of lung hyperinfl ation in COPD. Eur Respir Rev 2006 Dec; 15(100):661-667.
24. Agusti A. Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006 Aug; 3(6):478-481.
25. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic infl ammation and decline in lung function in a general population: a prospective study. Thorax 2007 Jun; 62(6):515-520.
26. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF, Jr., Lipinska I, O'Connor GT, Benjamin EJ. Systemic infl ammation and COPD: the Framingham Heart Study. Chest 2008 Jan; 133(1):19-25.
27. Hunninghake DB. Cardiovascular disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2(1):44-49.
28. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airfl ow obstruction revisited: an analysis of the Framingham off spring cohort. Am J Respir Crit Care Med 2009 Jul 1; 180(1):3-10.
29. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2(1):8-11.
30. Sin DD, Man SF. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 2005 Jan; 83(1):8-13.
31. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic infl ammation in chronic obstructive pulmonary disease. Circulation 2003 Mar 25; 107(11):1514-1519.
32. van Eeden SF, Yeung A, Quinlam K, Hogg JC. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2(1):61-67.
33. American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management of patients with COPD [Internet]. New York, NY; 2004. Available from: http:// www.thoracic.org/sections/copd/index.html
34. Zuwallack R, Nici L. Integrated care of the COPD patient: a pulmonary rehabilitation perspective. Breathe 2010; 6(4):313- 319.
35. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007 Oct; 30(4):616-622.
36. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The Effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005 Feb 15; 142(4):233-239.
37. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847-852.
38. Vilaro J, Ramirez-Sarmiento A, Martinez-Llorens JM, Mendoza T, Alvarez M, Sanchez-Cayado N, Vega A, Gimeno E, Coronell C, Gea J, Roca J, Orozco-Levi M. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 2010 Dec; 104(12):1896- 1902.
39. Kersul AL, Iglesias A, Rios A, Noguera A, Forteza A, Serra E, Agusti A, Cosio BG. Molecular mechanisms of infl ammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011 Apr; 47(4):176-183.
40. Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006 Jul; 130(1):133-142.
41. O'Reilly JF, Williams AE, Holt K, Rice L. Defi ning COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006 Dec; 15(6):346-353.
42. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeff ries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 May; 157(5(Pt 1)):1418-1422.
43. Halpern MT, Higashi MK, Bakst AW, Schmier JK. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: A literature review. J Manag Care Pharm 2003 Jul-Aug; 9(4):353-359.
44. Rennard SI, Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008 Dec 15; 5(9):878-883.
45. Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J, Rennard S. It's about time-directing our attention toward modifying the course of COPD. Respir Med 2008 Jun; 102 Suppl 1:S37-48.
46. Halpin DM, Tashkin DP. Defi ning disease modifi cation in chronic obstructive pulmonary disease. COPD 2009 Jun; 6(3):211-225.
47. Griffi ths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, Thomas J, Tunbridge J. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 2000 Jan 29; 355(9201):362-368.
48. Kaplan RM. The minimally clinically important diff erence in generic utility-based measures. COPD 2005 Mar; 2(1):91-97.
49. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir rit Care Med 2002 Sep 1; 166(5):675-679.
50. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356(8):775-789.
51. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9; 359(15):1543-1554.
52. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003 May 22; 348(21):2059-2073.
53. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, Burns DM, Prescott E, Vestbo J. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 2008 Oct; 32(4):844-853.
54. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fl uticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003 Feb 8; 361(9356):449-456.
55. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005 Aug; 26(2):214-222.
56. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE. Efficacy and tolerability of budesonide/ formoterol in one hydrofl uoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69(5):549-565.
57. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68(14):1975-2000.
58. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 Feb; 19(2):217-224.
59. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M. Effect of tiotropium on health-related quality of life as a primary Efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3(2):301-310.
60. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a oncedaily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005 Sep 6; 143(5):317-326.
61. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005 Mar; 127(3):809-817.
62. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D. Improvements in ymptomlimited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005 Sep; 128(3):1168-1178.
63. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fl uticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000 May 13; 320(7245):1297-1303.
64. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000 Dec 28; 343(26):1902-1909.
65. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999 Jun 24; 340(25):1948-1953.
66. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term Effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999 May 29; 353(9167):1819-1823.
67. Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefi ts of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003 Nov 1; 168(9):1034-1042.
68. Lacasse Y, Lecours R, Pelletier C, Begin R, Maltais F. Randomised trial of ambulatory oxygen in oxygen-dependent COPD. Eur Respir J 2005 Jun; 25(6):1032-1038.
69. Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981 Mar 28; 1(8222):681-686.
70. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980 Sep; 93(3):391-398.
71. Benzo R, Farrell MH, Chang CC, Martinez FJ, Kaplan R, Reilly J, Criner G, Wise R, Make B, Luketich J, Fishman AP, Sciurba FC. Integrating health status and survival data: the palliative Effect of lung volume reduction surgery. Am J Respir Crit Care Med 2009 Aug 1; 180(3):239-246.
72. Steele BG, Belza B, Cain KC, Coppersmith J, Lakshminarayan S, Howard J, Haselkorn JK. A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease. Arch Phys Med Rehabil 2008 Mar; 89(3):404-412.
73. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality - a systematic review. Respir Res 2005; 6:54.
74. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily lifein chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 May 1; 171(9):972-977.
75. Sewell L, Singh SJ, Williams JE, Collier R, Morgan MD. Can individualized rehabilitation improve functional independence in elderly patients with COPD? Chest 2005 Sep; 128(3):1194- 1200.
76. Walker PP, Burnett A, Flavahan PW, Calverley PM. Lower limb activity and its determinants in COPD. Thorax 2008 Aug; 63(8):683-689.
77. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006 Sep; 61(9):772- 778.
78. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr., Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994 Nov 16; 272(19):1497-1505.
79. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecifi ed subgroup analysis of a randomised controlled trial. Lancet 2009 Oct 3; 374(9696):1171-1178.
80. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: a pre-specifi ed analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010 Nov; 104(11):1659-1667.
81. Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M. Tiotropium as a fi rst maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010 Jul; 36(1):65-73.
82. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178(4):332-338.
83. Suissa S, Ernst P. Mega trials in COPD-clinical data analysis and design issues. Pneumonol Alergol Pol 2011; 79(3):227-231.
84. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fl uticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10:59.
85. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, Zuwallack R, Herrerias C. Pulmonary rehabilitation: Joint ACCP/AACVPR Evidencebased clinical practice Guidelines. Chest 2007 May; 131(5 Suppl):4S-42S.
86. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (4):CD001744.
87. Killian KJ. Limitation to muscular activity in chronic obstructive pulmonary disease. Eur Respir J 2004 Jul; 24(1):6-7.
88. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008 Sep; 32(3):637-643.
89. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995 Jun 1; 122(11):823-832.
90. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 Mar; 163(4):892-898.
91. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response Effect of oxygen on hyperinfl ation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001 Jul; 18(1):77-84.
92. Bedard ME, Brouillard C, Pepin V, Provencher S, Milot J, Lacasse Y, Leblanc P, Maltais F. Tiotropium improves walking endurance in chronic obstructive pulmonary disease. Eur Respir J 2012 Feb;39(2):265-271.
93. Okudan N, Gok M, Gokbel H, Suerdem M. Single dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary disease. Lung 2006 Jul-Aug; 184(4):201-204.
94. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinfl ation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004 Jun; 23(6):832-840.
95. Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, Neder JA. Effects of tiotropium and formoterol on dynamic hyperinfl ation and exercise endurance in COPD. Respir Med 2010 Sep; 104(9):1288-1296.
96. Worth H, Forster K, Eriksson G, Nihlen U, Peterson S, Magnussen H. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010 Oct; 104(10):1450-1459.
97. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996 Jul; 51(7):689-693.
98. Brouillard C, Pepin V, Milot J, Lacasse Y, Maltais F. Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Respir J 2008 Mar; 31(3):579-584.
99. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, oldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006 Jun 15; 173(12):1390-1413.
100. Guyatt GH, Townsend M, Keller J, Singer J, Nogradi S. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respiratory medicine 1991 Sep; 85 Suppl B:17-21; discussion 33-37.
101. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airfl ow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145(6):1321-1327.
102. Pitta F, Troosters T, Probst VS, Langer D, Decramer M, Gosselink R. Are patients with COPD more active after pulmonary rehabilitation? Chest 2008 Aug; 134(2):273-280.
103. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, Gliozzi F, Ciappi G. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995 Mar; 98(3):272-277.
104. Higgins MW, Th om T. Incidence, prevalence and mortality: intra-and inter-country diff erence. In: Hensley MJ, Saunders NA, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker; 1990:23-43.
105. Peters KD, Kochanek KD, Murphy SL. Deaths: final data for 1996. Natl Vital Stat Rep 1998 Nov 10; 47(9):1-100.
106. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995 Dec 20; 274(23):1852-1857.
107. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011 Mar 24; 364(12):1093-1103.
108. California Pulmonary Rehabilitation Collaborative Group. Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California. J Cardiopulm Rehabil 2004 Jan-Feb; 24(1):52-62.
109. Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2009; 77(3):305-313.
110. Imfeld S, Bloch KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006 Apr; 129(4):873-878.
111. Martinez FJ, Han MK, Andrei AC, Wise R, Murray S, Curtis JL, Sternberg A, Criner G, Gay SE, Reilly J, Make B, Ries AL, Sciurba F, Weinmann G, Mosenifar Z, DeCamp M, Fishman AP, Celli BR. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008 Sep 1; 178(5):491-499.
112. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med 2007 May 24; 356(21):2211-2212; author reply 2213-2214.
113. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9:32.
114. Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Anzueto A. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10:45.